CP
XLO icon

Caligan Partners’s Xilio Therapeutics XLO Stock Holding History

Caligan Partners’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-112,128
Closed -$943K – 32
2026
Q1 		$943K Buy
+112,128
New +$918K 0.06% 28

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Caligan Partners's XLO Position: Q2 2026 in Review

Caligan Partners sold out of Xilio Therapeutics (XLO) in Q2 2026, closing a stake of 112,128 shares — an estimated $943K sold.

Caligan Partners first reported a position in XLO in Q1 2026 and held it in 1 quarter. The position peaked at $943K in Q1 2026. 26 funds tracked by Wall St. Rank hold XLO as of Q2 2026.

  • Caligan Partners reported no remaining Xilio Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Caligan Partners sold 112,128 Xilio Therapeutics shares in Q2 2026, an estimated $943K.
  • Caligan Partners first reported a position in Xilio Therapeutics in Q1 2026 and held it in 1 quarter.
  • Caligan Partners's Xilio Therapeutics position peaked at $943K in Q1 2026.
  • 26 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q2 2026.

Based on Caligan Partners's 13F filing for Q2 2026, filed 14 Aug 2026.